Trial reportAmerican journal of physiology. Endocrinology and metabolism2014
Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone.
Trial report in American journal of physiology. Endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Exploring the efficacy and safety of a novel standardized ashwagandha (Journal of psychopharmacology (Oxford, England) · 2023Trial
- Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.Clinical endocrinology · 2016Trial
- Understanding the Secular Decline in Testosterone: Mechanisms, Consequences, and Clinical Perspectives.International journal of molecular sciences · 2026Review
- Article
- Review
- Gender-specific association between blood cell parameters and hyperuricemia in high-altitude areas.Frontiers in public health · 2024Article
- Prevalence of secondary erythrocytosis in men receiving testosterone therapy A matched-cohort analysis of intranasal gel, injections, and pellets.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- The Longitudinal Changes in Subcutaneous Abdominal Tissue and Visceral Adipose Tissue Volumetries Are Associated with Iron Status.International journal of molecular sciences · 2023Article
- 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells.Endocrinology · 2022Article
- Article
- Anabolic androgenic steroid-induced liver injury: An update.World journal of gastroenterology · 2022Review
- Review
- Protective role of estrogen against excessive erythrocytosis in Monge's disease.Experimental & molecular medicine · 2021Article
- Dysregulated hepcidin response to dietary iron in male mice with reduced Gnpat expression.Bioscience reports · 2020Article
- Iron and Advanced Glycation End Products: Emerging Role of Iron in Androgen Deficiency in Obesity.Antioxidants (Basel, Switzerland) · 2020Article
- Compromised endothelial function in transgender men taking testosterone.Clinical endocrinology · 2020Article
- An Intramuscular Injection of Mixed Testosterone Esters Does Not Acutely Enhance Strength and Power in Recreationally Active Young Men.Frontiers in physiology · 2020Article
- Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.American journal of physiology. Endocrinology and metabolism · 2018Article
- Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.Endocrine reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Testosterone (T) stimulates erythropoiesis and regulates iron homeostasis. However, it remains unknown whether the (type II) 5α-reduction of T to dihydrotestosterone (DHT) mediates these androgenic effects, as it does in some other tissues. Our purpose was to determine whether inhibition of type II 5α-reductase (via finasteride) alters red blood cell (RBC) production and serum markers of iron homeostasis subsequent to testosterone-enanthate (TE) administration in older hypogonadal men. Sixty men aged ≥60 yr with serum T <300 ng/dl or bioavailable T <70 ng/dl received treatment with TE (125 mg/wk) vs. vehicle paired with finasteride (5 mg/day) vs. placebo using a 2 × 2 factorial design. Over the course of 12 mo, TE increased RBC count 9%, hematocrit 4%, and hemoglobin 8% while suppressing serum hepcidin 57% (P < 0.001 for all measurements). Most of the aforementioned changes occurred in the first 3 mo of treatment, and finasteride coadministration did not significantly alter any of these effects. TE also reduced serum ferritin 32% (P = 0.002) within 3 mo of treatment initiation without altering iron, transferrin, or transferrin saturation. We conclude that TE stimulates erythropoiesis and alters iron homeostasis independently of the type II 5α-reductase enzyme. These results demonstrate that elevated DHT is not required for androgen-mediated erythropoiesis or for alterations in iron homeostasis that would appear to support iron incorporation into RBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.